Nephron SC, LLC Initiates Class II Recall of Albuterol Sulfate Inhalation Solution Due to Illegible Labeling
Nephron SC, LLC has initiated a Class II recall of 146,280 vials of Albuterol Sulfate Inhalation Solution due to illegible labels. This voluntary, firm-initiated action for lot AB6001, distributed nationwide, underscores critical quality control failures at the 503B outsourcing facility, posing significant supply chain and patient safety risks for procurement and regulatory teams.
FDA Class II Recall: Nephron SC, LLC's Albuterol Sulfate Inhalation Solution Affected by Illegible Labeling
Nephron SC, LLC, a prominent 503B outsourcing facility based in West Columbia, South Carolina, has initiated a voluntary, firm-initiated Class II recall of 146,280 vials of its Albuterol Sulfate Inhalation Solution, 0.5%, 25 mg/5 mL (5 mg/mL*). The recall, identified by the FDA as D-0479-2026 and initiated on March 17, 2026, stems from a critical quality control deficiency: illegible labeling. Specifically, affected product is from Lot AB6001, with an expiration date of January 15, 2027, and NDC 69374-330-05. This issue means that essential information on the product packaging, vital for safe and accurate administration, cannot be reliably read by healthcare professionals or patients. For procurement directors, this recall necessitates an immediate review of current inventory and supply agreements for Albuterol Sulfate. The Class II classification indicates that the use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This directly translates to potential patient safety incidents and increased liability exposure for healthcare providers utilizing these specific lots. Supply chain VPs must assess the immediate impact on their distribution networks, given the nationwide distribution pattern within the United States.
Operational Impact at Nephron SC's 503B Outsourcing Facility in West Columbia, SC
The recalled Albuterol Sulfate Inhalation Solution originated from Nephron SC, LLC's 503B outsourcing facility located at 4600 12th Street Extension, West Columbia, SC 29172. As a 503B facility, Nephron SC is authorized to compound sterile drugs for 'office use' by healthcare practitioners without a patient-specific prescription, operating under stricter Current Good Manufacturing Practice (cGMP) requirements than traditional compounding pharmacies. The illegible labeling issue points to a breakdown in the facility's quality assurance and control processes, specifically within its packaging and labeling operations. For regulatory affairs heads, this event underscores the FDA's heightened scrutiny on 503B facilities to ensure cGMP compliance, particularly concerning critical aspects like product identification and traceability. A deficiency in labeling, while not a direct contamination issue, can lead to significant medication errors, including incorrect dosing or administration of the wrong drug, thereby compromising patient safety. Business development executives should note that such quality lapses can erode confidence in outsourced sterile compounding services, potentially influencing future contracting decisions and market perception of 503B providers. Ensuring robust quality systems, from raw material sourcing to final product labeling, is paramount for maintaining operational integrity and market trust.
Supply Chain Vulnerabilities: Nationwide Distribution of Critical Respiratory Medication
The nationwide distribution of the recalled Albuterol Sulfate Inhalation Solution within the United States creates significant supply chain vulnerabilities for healthcare systems and pharmacies. Albuterol Sulfate is a critical bronchodilator used for treating bronchospasm in patients with reversible obstructive airway disease, including asthma and COPD. Any disruption in its supply, even for specific lots, can have immediate clinical consequences. Procurement directors must urgently identify if their organizations have received Lot AB6001 (NDC 69374-330-05) and initiate quarantine and return procedures. The recall of 146,280 vials represents a substantial volume that will need to be replaced, potentially straining existing supply agreements and leading to temporary shortages in certain regions. Supply chain VPs need to assess their inventory resilience and the robustness of their supplier qualification programs. This incident highlights the necessity for diversified sourcing strategies, even for seemingly stable products, to mitigate the impact of quality-related recalls. Furthermore, the administrative burden of managing a Class II recall, including product identification, segregation, and return logistics, will incur significant operational costs and divert resources, impacting overall operational efficiency for all downstream stakeholders.
Mitigating Risk: Proactive Sourcing and Supplier Qualification for Albuterol Sulfate
Given the absence of named alternative suppliers in the current intelligence, procurement teams must proactively identify and qualify new sources for Albuterol Sulfate Inhalation Solution to mitigate the supply risk exposed by Nephron SC, LLC's recall. The critical nature of Albuterol Sulfate as a widely used respiratory medication means that any supply interruption can directly impact patient care. Organizations should immediately initiate a comprehensive review of their approved supplier lists, focusing on manufacturers with robust cGMP compliance records and established quality systems, particularly concerning labeling and packaging controls. This process involves not only identifying potential new suppliers but also conducting thorough audits to ensure their manufacturing processes meet stringent regulatory standards and can reliably deliver product quality. Qualification timelines for new pharmaceutical suppliers can extend from several months to over a year, depending on the complexity of the product and the regulatory requirements. Therefore, early engagement is crucial. Business development executives should consider this an opportunity to assess the competitive landscape for sterile compounding services and identify partners with impeccable quality track records, leveraging this incident to reinforce their own commitment to supply chain integrity and patient safety.
Broader Regulatory Environment: FDA Scrutiny on Pharmaceutical Quality and Labeling
This Class II recall by Nephron SC, LLC occurs within a broader context of intensified FDA scrutiny on pharmaceutical manufacturing quality and compliance, particularly for sterile products and outsourcing facilities. While this specific event concerns illegible labeling, recent parallel events highlight a persistent focus on quality assurance across the industry. For instance, Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility assurance failures in June 2026, and Spectra Medical Devices encountered a similar Class II recall for Lidocaine HCl Injection due to sterility deficiencies around the same time. Guardian Drug Co. Inc. also initiated nationwide Class II recalls for metallic contamination in antacids. These incidents, though distinct in their specific deficiencies, collectively underscore the FDA's unwavering expectation for robust cGMP adherence in all aspects of drug manufacturing, from sterility to final product presentation. Regulatory affairs heads must recognize that the FDA is actively monitoring and enforcing quality standards across the board. This necessitates continuous internal audits, investment in advanced quality control technologies, and proactive remediation of any identified gaps to prevent regulatory actions that can lead to significant operational disruptions, market withdrawal costs, and reputational damage. The consistent regulatory pressure means that all pharmaceutical companies, including 503B outsourcing facilities, must prioritize a culture of quality to ensure uninterrupted supply and patient safety.